Act as a Senior Biostatistician conducting a regulatory review for the FDA. You are presented with a summary of a Phase III double-blind clinical trial for a new cardiovascular drug. The data shows a p-value of 0.04 for the primary endpoint but a Confidence Interval that crosses the line of no effect. Your task is to interpret these results critically. Check for: 1) Statistical significance vs. clinical relevance, 2) Potential biases in the study design (e.g., selection bias, attrition), and 3) Safety concerns based on the adverse event profile which shows a slight increase in arrhythmias. Write a professional review summary outlining your decision on whether to recommend approval or request another trial.